Fresenius SE EBITDA 2016-2024 | FSNUY
Fresenius SE annual and quarterly EBITDA history from 2016 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Fresenius SE EBITDA for the quarter ending June 30, 2024 was $0.629B, a 54.18% decline year-over-year.
- Fresenius SE EBITDA for the twelve months ending June 30, 2024 was $1.416B, a 77.26% decline year-over-year.
- Fresenius SE 2023 annual EBITDA was $2.837B, a 57.22% decline from 2022.
- Fresenius SE 2022 annual EBITDA was $6.631B, a 17.87% decline from 2021.
- Fresenius SE 2021 annual EBITDA was $8.075B, a 0.44% decline from 2020.
Fresenius SE Annual EBITDA
(Millions of US $) |
| 2023 |
$2,837 |
| 2022 |
$6,631 |
| 2021 |
$8,075 |
| 2020 |
$8,110 |
| 2019 |
$7,933 |
| 2018 |
$7,890 |
| 2017 |
$6,811 |
| 2016 |
$6,086 |
| 2015 |
$5,541 |
Fresenius SE Quarterly EBITDA
(Millions of US $) |
| 2024-06-30 |
$629 |
| 2024-03-31 |
$923 |
| 2023-12-31 |
$82 |
| 2023-09-30 |
$-217 |
| 2023-06-30 |
$1,372 |
| 2023-03-31 |
$1,600 |
| 2022-12-31 |
$1,664 |
| 2022-09-30 |
$1,592 |
| 2022-06-30 |
$1,586 |
| 2022-03-31 |
$1,790 |
| 2021-12-31 |
$2,177 |
| 2021-09-30 |
$1,933 |
| 2021-06-30 |
$2,002 |
| 2021-03-31 |
$1,963 |
| 2020-12-31 |
$2,128 |
| 2020-09-30 |
$2,107 |
| 2020-06-30 |
$1,939 |
| 2020-03-31 |
$1,936 |
| 2019-12-31 |
$2,171 |
| 2019-09-30 |
$1,940 |
| 2019-06-30 |
$1,907 |
| 2019-03-31 |
$1,915 |
| 2018-12-31 |
$1,852 |
| 2018-09-30 |
$1,597 |
| 2018-06-30 |
$2,739 |
| 2018-03-31 |
$1,702 |
| 2017-12-31 |
$1,680 |
| 2017-09-30 |
$1,776 |
| 2017-06-30 |
$1,692 |
| 2017-03-31 |
$1,662 |
| 2016-12-31 |
$1,695 |
| 2016-09-30 |
$1,506 |
| 2016-06-30 |
$1,520 |
| 2016-03-31 |
$1,365 |
| 2015-12-31 |
$7,951 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.458B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
